929-P: Dulaglutide Shows Sustained A1C Reduction: Two-Year U.S. Real-World Study

Abstract

The primary objective of this retrospective, observational study was to evaluate glycemic control over a 2 yr follow-up period among dulaglutide (DU) initiators with continuous treatment using U.S. claims data from the HealthCore Integrated Research Database (HIRD®) between May 2014 and May 2019 (index date=earliest DU fill during index period between November 2014 and May 2017). Patients (pts) ≥18 yrs old with T2D, ≥1 pharmacy claim for DU during the index period, continuous enrollment in the 6 months pre index (=baseline [BL]) and 2 yrs post index, ≥1 claim for DU or ≥60 days supply in every quarter during the 2-yr follow-up period, and ≥1 A1C result at both BL and 2 yrs were included. At BL, pts (N=872; 47.5% female) were (mean ± SD) 54.5 ± 8.2 yrs old with an A1C of 8.7 ± 1.8%. Antihyperglycemic medication use pre/post index included: insulin, 28%/35%; DPP-4 inhibitors, 37%/20%; SGLT2 inhibitors, 29%/44%. More than two-thirds were being treated for dyslipidemia, hypertension, or CVD. Key results are included in the Figure. Significant A1C reduction was observed from BL to 2 yrs (-1.3%, p<0.0001). Forty-three percent of pts achieved an A1C <7% and 74% achieved an A1C <8% at 2 yrs. In this real-world study among DU initiators with continuous treatment, a clinically significant reduction in A1C was seen at the 3-month assessment and persisted for up to 2 yrs. These data support the use of DU as an effective long-term treatment for T2D in clinical practice. Disclosure R. Mody: Employee; Self; Eli Lilly and Company. M. Yu: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; LifeLabs. Stock/Shareholder; Self; Eli Lilly and Company. M. Grabner: Research Support; Self; Eli Lilly and Company. K. Boye: Employee; Self; Lilly Diabetes. Stock/Shareholder; Self; Eli Lilly and Company. C. Teng: Research Support; Self; Eli Lilly and Company. A. Kwan: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Eli Lilly and Company. Stock/Shareholder; Spouse/Partner; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company.